C
CalciMedica, Inc. (CALC)
NCM – Real Time Price. Currency in USD
0.63
+0.04 (6.63%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.63
+0.04 (6.63%)
At close: May 12, 2026, 4:00 PM EDT
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
| Name | Position |
|---|---|
| Dr. A. Rachel Leheny Ph.D. | CEO & Director |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor |
| Dr. Sudarshan Hebbar M.D. | Chief Medical Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 10-K/A | ck0001534133-20251231.htm |
| 2026-03-18 | 8-K | d101411d8k.htm |
| 2026-03-09 | CORRESP | filename1.htm |
| 2026-03-03 | S-3 | d61343ds3.htm |
| 2026-01-28 | 8-K | d40225d8k.htm |
| 2025-11-12 | 10-Q | ck0001534133-20250930.htm |
| 2025-08-12 | 8-K | ck0001534133-20250812.htm |
| 2025-06-27 | S-8 POS | d917898ds8pos.htm |
| 2025-06-27 | 8-K | d12150d8k.htm |
| 2025-06-24 | S-8 | d949209ds8.htm |
| Mr. Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board |
| Mr. John M. Dunn J.D. | General Counsel |
| Mr. Michael J. Dunn B.A., M.B.A. | President & COO |
| Mr. Stephen B. Bardin | Chief Financial Officer |